scholarly journals Immune Responses of Elk to Initial and Booster Vaccinations with Brucella abortus Strain RB51 or 19

2006 ◽  
Vol 13 (10) ◽  
pp. 1098-1103 ◽  
Author(s):  
S. C. Olsen ◽  
S. J. Fach ◽  
M. V. Palmer ◽  
R. E. Sacco ◽  
W. C. Stoffregen ◽  
...  
Keyword(s):  
Immune Responses ◽  
Cervus Elaphus ◽  
Brucella Abortus ◽  
Bos Taurus ◽  
Booster Vaccination ◽  
Immunoglobulin M ◽  
Treatment Groups ◽  
Flow Cytometric ◽  
Cellular Immune ◽  
And Control

ABSTRACT Previous studies have suggested that currently available brucellosis vaccines induce poor or no protection in elk (Cervus elaphus nelsoni). In this study, we characterized the immunologic responses of elk after initial or booster vaccination with Brucella abortus strains RB51 (SRB51) and 19 (S19). Elk were vaccinated with saline or 1010 CFU of SRB51 or S19 (n = seven animals/treatment) and booster vaccinated with a similar dosage of the autologous vaccine at 65 weeks. Compared to nonvaccinates, elk vaccinated with SRB51 or S19 had greater (P < 0.05) antibody responses to SRB51 or S19 after initial vaccination and after booster vaccination. Compared to nonvaccinated elk, greater (P < 0.05) proliferative responses to autologous antigen after initial vaccination occurred at only a few sample times in SRB51 (6, 14, and 22 weeks) and S19 (22 weeks) treatment groups. In general, proliferative responses of vaccinates to nonautologous antigens did not differ (P > 0.05) from the responses of nonvaccinated elk. Gamma interferon production in response to autologous or nonautologous Brucella antigens did not differ (P > 0.05) between controls and vaccinates after booster vaccination. Flow cytometric techniques suggested that proliferation occurred more frequently in immunoglobulin M-positive cells, with differences between vaccination and control treatments in CD4+ and CD8+ subset proliferation detected only at 22 weeks after initial vaccination. After booster vaccination, one technique ([3H]thymidine incorporation) suggested that proliferative responses to SRB51 antigen, but not S19 antigen, were greater (P < 0.05) in vaccinates compared to the responses of nonvaccinates. However, in general, flow cytometric and other techniques failed to detect significant anamnestic responses to autologous or nonautologous Brucella antigens in S19 or SRB51 vaccinates after booster vaccination. Although some cellular immune responses were detected after initial or booster vaccination of elk with SRB51 or S19, our data suggest that responses tend to be transient and much less robust than previously reported in SRB51-vaccinated cattle (Bos taurus) or bison (Bison bison). These data may explain why the vaccination of elk with S19 and SRB51 induces poor protection against brucellosis.

scholarly journals Immune Responses and Efficacy of Brucella Abortus Strain RB51 in Bison After Delivery in a Dry Dart Formulation or by Parenteral Inoculation

2021 ◽  
Vol 8 ◽  
Author(s):  
Steven C. Olsen ◽  
Paola M. Boggiatto ◽  
Pauline Nol ◽  
Matthew P. McCollum ◽  
Jack C. Rhyan
Keyword(s):  
Immune Responses ◽  
Brucella Abortus ◽  
Mononuclear Cells ◽  
Booster Vaccination ◽  
The Novel ◽  
Peripheral Blood Mononuclear ◽  
Parenteral Delivery ◽  
Colony Forming Units ◽  
Humoral Responses ◽  
Cellular Immune

Bison (Bison bison) heifer calves (n = 32) were randomly assigned to control or vaccination with 1010 colony-forming units of Brucella abortus strain RB51 (RB51) vaccine by single or boostered parenteral delivery, or by surgical implantation of a dry dart formulation (n = 8/trt). Serum and/or peripheral blood mononuclear cells (PBMC) were obtained at 0, 4, 8, 13, 16, 21, and 24 wks after initial vaccination and at 0, 4, 8, 12, 15, 22, and 27 wks after booster vaccination to characterize humoral and cellular immune responses to RB51. Bison in both RB51 vaccination treatments demonstrated greater (P &lt; 0.0001) serum humoral responses when compared to non-vaccinates, with parenteral vaccinates demonstrating greater (P &lt; 0.01) responses when compared to mean responses of bison inoculated with the dry dart. Only the booster vaccinated treatment demonstrated greater (P &lt; 0.0001) humoral responses than control bison in samples collected after re-inoculation. At 4, 8, 12, 16, and 24 wks after initial vaccination, PBMC from parenteral RB51 vaccinates demonstrated greater proliferative responses to RB51 when compared to responses of control animals. In comparison, bison inoculated with the RB51 dry dart did not demonstrate greater (P &gt; 0.05) proliferative responses when compared to responses of non-vaccinates. Bison were pasture bred and pregnant animals experimentally challenged in mid-gestation with 107 CFU of B. abortus strain 2,308. Bison in parenteral vaccination treatments had reduced (P &lt; 0.05) abortions and infection in uterine and fetal samples as compared to non-vaccinated bison, with booster vaccinates tending to have the lowest colonization (CFU/gm) in tissues. In comparison, the dry dart formulation did reduce abortion (P &lt; 0.05) but not infection (P &gt; 0.05) in most tissues when compared to non-vaccinated bison. The results of this study reaffirm the efficacy of boostered parenteral vaccination of bison with RB51 in preventing brucellosis. Our data also suggests that the novel dry dart RB51 formulation does not induce sufficient efficacy in bison after a single inoculation.

scholarly journals Immune Responses and Protection against Experimental Brucella suis Biovar 1 Challenge in Nonvaccinated or B. abortus Strain RB51-Vaccinated Cattle

2010 ◽  
Vol 17 (12) ◽  
pp. 1891-1895 ◽  
Author(s):  
S. C. Olsen ◽  
S. G. Hennager
Keyword(s):  
Immune Responses ◽  
Experimental Infection ◽  
Brucella Abortus ◽  
Agglutination Test ◽  
Saline Control ◽  
Infected Cattle ◽  
Infection Rates ◽  
Treatment Groups ◽  
Brucella Suis ◽  
Fluorescence Polarization Assay

ABSTRACT Twenty Hereford heifers approximately 9 months of age were vaccinated with saline (control) or 2 × 1010 CFU of the Brucella abortus strain RB51 (RB51) vaccine. Immunologic responses after inoculation demonstrated significantly greater (P < 0.05) antibody and proliferative responses to RB51 antigens in cattle vaccinated with RB51 than in the controls. Pregnant cattle received a conjunctival challenge at approximately 6 months of gestation with 107 CFU of B. suis bv. 1 strains isolated from naturally infected cattle. The fluorescence polarization assay and the buffered acid plate agglutination test had the highest sensitivities in detecting B. suis-infected cattle between 2 and 12 weeks after experimental infection. Serologic responses and lymphocyte proliferative responses to B. suis antigens did not differ between control and RB51 vaccinees after experimental infection. No abortions occurred in cattle in either treatment group after challenge, although there appeared to be an increased incidence of retained placenta after parturition in both the control and the RB51 vaccination treatment groups. Our data suggest that the mammary gland is a preferred site for B. suis localization in cattle. Vaccination with RB51 did not reduce B. suis infection rates in maternal or fetal tissues. In conclusion, although B. suis is unlikely to cause abortions and fetal losses in cattle, our data suggest that RB51 vaccination will not protect cattle against B. suis infection after exposure.

scholarly journals Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination

2018 ◽  
Vol 9 ◽  
Author(s):  
Saskia van der Lee ◽  
Debbie M. van Rooijen ◽  
Mary-Lène de Zeeuw-Brouwer ◽  
Marjan J. M. Bogaard ◽  
Pieter G. M. van Gageldonk ◽  
...  
Keyword(s):  
Immune Responses ◽  
Booster Vaccination ◽  
Cellular Immune Responses ◽  
Cellular Immune

scholarly journals Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

2020 ◽  
Author(s):  
Neil Goldstein ◽  
Viki Bockstal ◽  
Stephan Bart ◽  
Kerstin Luhn ◽  
Cynthia Robinson ◽  
...  
Keyword(s):  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Ebola Virus ◽  
Phase 1 ◽  
Booster Vaccination ◽  
Controlled Study ◽  
Adenovirus Serotype ◽  
Cellular Immune Responses ◽  
High Doses ◽  
Cellular Immune

Abstract Background This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360. Methods Healthy US adults (N = 164) randomized into 10 groups received saline placebo or standard or high doses of Ad26 or MVA in 2-dose regimens at 7-, 14-, 28-, or 56-day intervals; 8 groups received booster Ad26 or MVA vaccinations on day 360. Participants reported solicited and unsolicited reactogenicity; we measured immunoglobulin G binding, neutralizing antibodies and cellular immune responses to Ebola virus glycoprotein. Results All regimens were well tolerated with no serious vaccine-related adverse events. Heterologous (Ad26,MVA [dose 1, dose 2] or MVA,Ad26) and homologous (Ad26,Ad26) regimens induced humoral and cellular immune responses 21 days after dose 2; responses were higher after heterologous regimens. Booster vaccination elicited anamnestic responses in all participants. Conclusions Both heterologous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adults, regardless of interval or dose level. Heterologous 2-dose Ad26,MVA regimens containing an Ebola virus insert induce strong, durable humoral and cellular immune responses. Immunological memory was rapidly recalled by booster vaccination, suggesting that Ad26 booster doses could be considered for individuals at risk of Ebola infection, who previously received the 2-dose regimen.

scholarly journals Efficacy of Dart or Booster Vaccination with Strain RB51 in Protecting Bison against Experimental Brucella abortus Challenge

2012 ◽  
Vol 19 (6) ◽  
pp. 886-890 ◽  
Author(s):  
S. C. Olsen ◽  
C. S. Johnson
Keyword(s):  
Brucella Abortus ◽  
Protective Immunity ◽  
Booster Vaccination ◽  
Bison Bison ◽  
Control Group ◽  
Effective Strategy ◽  
Content Type ◽  
Treatment Groups ◽  
Uterine Infection ◽  
Single Vaccination

ABSTRACTThis study characterized the efficacy of theBrucella abortusstrain RB51 vaccine in bison when delivered by single intramuscular vaccination (hand RB51), by single pneumatic dart delivery (dart RB51), or as two vaccinations approximately 13 months apart (booster RB51) in comparison to control bison. All bison were challenged intraconjunctivally in midgestation with 107CFU ofB. abortusstrain 2308 (S2308). Bison were necropsied and sampled within 72 h of abortion or delivery of a live calf. Compared to nonvaccinated bison, bison in the booster RB51 treatment had a reduced (P< 0.05) incidence of abortion, uterine infection, or infection in maternal tissues other than the mammary gland at necropsy. Bison in single-vaccination treatment groups (hand RB51 and dart RB51) did not differ (P> 0.05) from the control group in the incidence of abortion or recovery of S2308 from uterine, mammary, fetal, or maternal tissues at necropsy. Compared to nonvaccinated animals, all RB51 vaccination groups had reduced (P< 0.05) mean colonization or incidence of infection in at least 2 of 4 target tissues, with the booster RB51 group having reduced (P< 0.05) colonization and incidence of infection in all target tissues. Our data suggest that booster vaccination of bison with RB51 enhances protective immunity againstBrucellachallenge compared to single vaccination with RB51 by hand or by pneumatic dart. Our study also suggests that an initial vaccination of calves followed by booster vaccination as yearlings should be an effective strategy for brucellosis control in bison.

scholarly journals Pathological changes inducing by S.aureus in immunodeficiency mice immunized with Soluble Culture Filtrate S.aureus Antigens (SCFAgs)

2013 ◽  
Vol 12 (1) ◽  
pp. 71
Author(s):  
H. H. K. AL-Byattee
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Culture Filtrate ◽  
Post Inoculation ◽  
Bacterial Isolation ◽  
Positive Group ◽  
Treatment Groups ◽  
Humoral Immune ◽  
Sterile Normal Saline ◽  
Cellular Immune

In order to determine the influence of Soluble Culture Filtrate S.aureus Antigens (SCFAgs)on S.aureus infection in Mitomicin c immunosupression mice, seventy four white mice, both sex,7-8 weeks age were divided randomly into five groups.1st group(n=16 ) was immunized with 0.4ml of S.aureus CFSAgs (concentration of protein( 4.2mg/ml) ,i/p two doses, 2 weeks intervals. 2nd group(n=16) was injected with mitomycine C ,(1mg/kg B.W) I/p three time /week for 4 weeks. 3ed group (n=16) was immunized with CFSAgs as 1st group and treated with mitomycin as 2nd group. 4th group(n=10) was inoculated with (0.4ml) I/P with1X109 CFU/ML of viable virulent. S.aureus and was served as control positive group. 5th group (n=16) was inoculated with 0.5ml sterile normal saline. Cellular and humoral immune response were recorded at 28-30 day post immunization, skin test and passive heam agglutination test respectively, then all animals of immunized and treatment groups were challenge with S,aureus as control positive group. The results explained that animals treatment with MMC were died during (18) hrs post inoculation with virulent viable S.aureus with very heavy bacterial isolation, animal of control positive group were died at( 24)hrs post infection with heavy bacterial isolation The results revealed that immunization with CFSAgs elicited both humoral and cellular immune responses, the level values of both arms of immune response were lower animal treatment with MMC, Severe pathological lesions were seen in examined organs of control positive group but these lesions are more extensive in animal treatment with MMC. The main lesions in examined organs of these animals are suppurative inflammation ,congestion ,apoptosis and necrosis.. We conclusion that MMC induce immunosuppression condition and immunization with CFSAgs can improve the immune responses in the animals that are suffering from immunosuppression.

scholarly journals BacMam virus-based surface display for HCV E2 glycoprotein induces strong cross-neutralizing antibodies and cellular immune responses in vaccinated mice

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Ebrahim Kord ◽  
Farzin Roohvand ◽  
Jean Dubuisson ◽  
Thibaut Vausselin ◽  
Hosein Nasr Azadani ◽  
...  
Keyword(s):  
Immune Responses ◽  
Mammalian Cells ◽  
Neutralizing Antibodies ◽  
Surface Display ◽  
Immunogold Electron Microscopy ◽  
Cellular Immune Responses ◽  
Boost Immunization ◽  
Ifn Γ ◽  
Cellular Immune ◽  
And Control

Abstract Background Despite recent advancements, limitations in the treatment and control of hepatitis C virus (HCV) infection reprioritized the studies for invention of an efficient HCV vaccine to elicit strong neutralizing antibodies (NAbs) and cellular responses. Methods Herein, we report molecular construction of a BacMam virus-based surface display for a subtype-1a HCV gpE2 (Bac-CMV-E2-gp64; Bac) that both expressed and displayed gpE2 in mammalian cells and bacouloviral envelope, respectively. Results Assessments by western blotting, Immunofluorescence and Immunogold-electron microscopy indicated the proper expression and incorporation in insect cell and baculovirus envelope, respectively. Mice immunized in three different prime-boost immunization groups of: Bac/Bac, Bac/Pro (bacoulovirus-derived gpE2) and Bac/DNA (plasmid DNA (pCDNA)-encoding gpE2) developed high levels of IgG and IFN-γ (highest for Bac/Bac group) indicating the induction of both humeral and cellular immune responses. Calculation of the IgG2a/IgG1 and IFN-γ/IL-4 ratios indicated a Th1 polarization of immune responses in the Bac/Bac and Bac/DNA groups but a balanced Th1-Th2 phenotype in the Bac/Pro group. Sera of the mice in the Bac/Bac group provided the highest percentage of cross-NAbs against a subtype-2a HCVcc (JFH1) compared to Bac/Pro and Bac/DNA groups (62% versus 41% and 6%). Conclusions Results indicated that BacMam virus-based surface display for gpE2 might act as both subunit and DNA vaccine and offers a promising strategy for development of HCV vaccine for concurrent induction of strong humoral and cellular immune responses.

scholarly journals Control and Preventive Study of Brucellosis by Using

2017 ◽  
Vol 3 (6) ◽  
pp. 234
Author(s):  
Rahmahani J ◽  
Handijatno D ◽  
Tyaningsih W ◽  
Suwarno Suwarno
Keyword(s):  
Immune Response ◽  
Sodium Chloride ◽  
Antibody Response ◽  
Brucella Abortus ◽  
Cellular Response ◽  
Booster Vaccination ◽  
Humoral Response ◽  
Igg Antibody ◽  
Whole Cells ◽  
Cellular Immune

The aims of this research is to determine the ability of sub unit lipopolysacharide(LPS) vaccine of Brucella abortus strain S-19 in mice and goat, including IgM and sub classes IgG antibody humoral response, cellular mediated immune response (IL-2, IFN- γ) in mice, also IgG as humoral immunity, IL-4 and IL-12 as cellular immunity, comparison affectivity with Brucella abortus strain RB-51 vaccine in goat . This research has two steps methods. Step first, 30 Balb C mice were divided into 3 groups and vaccinated subcutaneously, First group injectedB. abortus S-19, second group injected LPS and third group injected sodium chloride solution. Booster vaccination was conducted every two weeks till the eight week after first vaccination. The second step performed vaccinated to 30 goats divided into three groups. First group was injected by subcutaneous LPS 50 µg/ml and second group injected LPS 100 µg/ml and the third group injected with sodium chloride as control. Booster vaccination conducted 2 weeks after first vaccination and second vaccination. Result of the research conferred. Result research, antibody response in mice showed vaccination by LPS of B. abortus S-19 showed higher titer than vaccination by whole cells but inverse cellular response. The both vaccines showed induce subclass antibody response, vaccination by LPS tendency to IgM response but vaccination by Whole cells active vaccine tendency to IgG1, IgG 2a and IgG2b. Response antibody in goat on two weeks after first vaccination, vaccination with LPS of B. abortus S-19, dose 50 µg/ml failed or zero titer IgG response but dose 100 µg/ml was 500response antibody on two weeks after second vaccination by dose 50 µg/ml was 340 but by dose 100 µg/ml was 960, while cellular IL-12 response two weeks after first vaccination by dose 50 µg/ml was 22.88 pg/ml but by 100 µg/ml was 62.15 pg/ml. Response cellular IL -12 two weeks after second vaccination 50 µg/ml was 12.04 pg/ml while by dose100 µg/ml was 130.88pg/ml    Cellular immune response IL-4 on two weeks after first vaccination, dose 50 µg/ml showed 55.57 pg/ml but by dose100 µg/ml was 49.35 pg/ ml. Response cellular IL-4 on two weeks after second vaccination by dose 50 µg/ml  was 22.17 pg/ml but by dose 100 µg/ml was 143.89 pg/ml Keyword: Vaccine sub-unit LPS of Brucella abortus S-19, Humoral antibody, Cellular antibody

Sign in / Sign up

Export Citation Format

Share Document